|
1
|
Taylor BS, Barretina J, Maki RG, Antonescu
CR, Singer S and Ladanyi M: Advances in sarcoma genomics and new
therapeutic targets. Nat Rev Cancer. 11:541–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Szkandera J, Absenger G, Liegl-Atzwanger
B, Pichler M, Stotz M, Samonigg H, Glehr M, Zacherl M, Stojakovic
T, Gerger A and Leithner A: Elevated preoperative
neutrophil/lymphocyte ratio is associated with poor prognosis in
soft-tissue sarcoma patients. Br J Cancer. 108:1677–1683. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan JY, Zhang Z, Chew W, Tan GF, Lim CL,
Zhou L, Goh WL, Poon E, Somasundaram N, Selvarajan S, et al:
Biological significance and prognostic relevance of peripheral
blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Sci
Rep. 8:119592018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Somasundaram N, Chan SH, Quek R and Ngeow
J: Chapter 43-Advances in Sarcoma Genomics and Therapeutic
Management. In: Oncogenomics. Dammacco F and Silvestris F: Academic
Press; pp. 609–621. 2019
|
|
6
|
Penel N, Ray-Coquard I, Bal-Mahieu C,
Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou
B, Lansiaux A, et al: Low level of baseline circulating VEGF-A is
associated with better outcome in patients with vascular sarcomas
receiving sorafenib: An ancillary study from a phase II trial.
Target Oncol. 9:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Serranogarcia C, Heinrich MC, Zhu M, Raut
CP, Eilers G, Ravegnini G, Demetri GD, Bauer S, Fletcher JA and
George S: In vitro and in vivo activity of regorafenib (REGO) in
drug-resistant gastrointestinal stromal tumors (GIST). J Clin
Oncol. 31 (Suppl 15):10510. 2013. View Article : Google Scholar
|
|
8
|
Rickel K, Fang F and Tao J: Molecular
genetics of osteosarcoma. Bone. 102:69–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maguire M: Comment on: Early symptoms of
bone and soft tissue sarcomas: Could they be diagnosed earlier? Ann
R Coll Surg Engl. 94:4512012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scurr M and Judson I: Sarcoma. Cancer
Chemother Biol Response Modif. 21:637–653. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hastings CA, Torkildson JC and Agrawal AK:
Sarcomas of the Soft Tissues and Bone. Handbook of Pediatric
Hematology and Oncology: Children's Hospital & Research Center
Oakland: Second edition. pp. 183–192. 2012, View Article : Google Scholar
|
|
13
|
Sinha S and Peach AH: Diagnosis and
management of soft tissue sarcoma. BMJ. 341:c71702010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whelan J, McTiernan A, Cooper N, Wong YK,
Francis M, Vernon S and Strauss SJ: Incidence and survival of
malignant bone sarcomas in England 1979–2007. Int J Cancer.
131:E508–E517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang L, Chen Y, Cui T, Knösel T, Zhang Q,
Geier C, Katenkamp D and Petersen I: Identification of biomarkers
to distinguish clear cell sarcoma from malignant melanoma. Hum
Pathol. 43:1463–1470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Brummelen EMJ, de Boer A, Beijnen JH
and Schellens JHM: BRAF mutations as predictive biomarker for
response to Anti-EGFR monoclonal antibodies. Oncologist.
22:864–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Evola FR, Costarella L, Pavone V, Caff G,
Cannavò L, Sessa A, Avondo S and Sessa G: Biomarkers of
osteosarcoma, chondrosarcoma, and ewing sarcoma. Front Pharmacol.
8:1502017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hutanu D, Popescu R, Stefanescu H, Pirtea
L, Candea A, Sarau C, Boruga O, Mehdi L, Ciuca I and Tanasescu S:
The molecular genetic expression as a novel biomarker in the
evaluation and monitoring of patients with osteosarcoma-subtype
bone cancer disease. Biochem Genet. 55:291–299. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cancer Genome Atlas Research Network, .
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas Pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network, .
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Research Network, .
Electronic address simpleelizabeth.demicco@sinaihealthsystem.ca.
et al Comprehensive and integrated genomic characterization of
adult soft tissue sarcomas. Cell. 171:950–965.e28. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chudasama P, Mughal SS, Sanders MA,
Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M,
Zapatka M, et al: Integrative genomic and transcriptomic analysis
of leiomyosarcoma. Nat Commun. 9:1442018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mertens F, Antonescu CR and Mitelman F:
Gene fusions in soft tissue tumors: Recurrent and overlapping
pathogenetic themes. Genes Chromosomes Cancer. 55:291–310. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Italiano A, Bianchini L, Gjernes E,
Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A,
Mainguené C, Terrier P, et al: Clinical and biological significance
of CDK4 amplification in well-differentiated and dedifferentiated
liposarcomas. Clin Cancer Res. 15:5696–5703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chibon F, Lagarde P, Salas S, Pérot G,
Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B,
et al: Validated prediction of clinical outcome in sarcomas and
multiple types of cancer on the basis of a gene expression
signature related to genome complexity. Nat Med. 16:781–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sankar S and Lessnick SL: Promiscuous
partnerships in Ewing's sarcoma. Cancer Genet. 204:351–365. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fligman I, Lonardo F, Jhanwar SC, Gerald
WL, Woodruff J and Ladanyi M: Molecular diagnosis of synovial
sarcoma and characterization of a variant SYT-SSX2 fusion
transcript. Am J Pathol. 147:1592–1599. 1995.PubMed/NCBI
|
|
28
|
Antonescu CR, Tschernyavsky SJ, Woodruff
JM, Jungbluth AA, Brennan MF and Ladanyi M: Molecular diagnosis of
clear cell sarcoma: Detection of EWS-ATF1 and MITF-M transcripts
and histopathological and ultrastructural analysis of 12 cases. J
Mol Diagn. 4:44–52. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kubota T: Gastrointestinal stromal tumor
(GIST) and imatinib. Int J Clin Oncol. 11:184–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stacchiotti S, Crippa F, Messina A,
Pilotti S, Gronchi A, Blay JY and Casali PG: Response to imatinib
in villonodular pigmented synovitis (PVNS) resistant to nilotinib.
Clin Sarcoma Res. 3:82013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rausch JL, Boichuk S, Ali AA, Patil SS,
Liu L, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, et al:
Opposing roles of KIT and ABL1 in the therapeutic response of
gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Oncotarget. 8:4471–4483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dickson MA, Tap WD, Keohan ML, D'Angelo
SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy
MM, et al: Phase II trial of the CDK4 inhibitor PD0332991 in
patients with advanced CDK4-amplified well-differentiated or
dedifferentiated liposarcoma. J Clin Oncol. 31:2024–2028. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Knezevich SR, McFadden DE, Tao W, Lim JF
and Sorensen PH: A novel ETV6-NTRK3 gene fusion in congenital
fibrosarcoma. Nat Genet. 18:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haller F, Knopf J, Ackermann A, Bieg M,
Kleinheinz K, Schlesner M, Moskalev EA, Will R, Satir AA,
Abdelmagid IE, et al: Paediatric and adult soft tissue sarcomas
with NTRK1 gene fusions: A subset of spindle cell sarcomas unified
by a prominent myopericytic/haemangiopericytic pattern. J Pathol.
238:700–710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gibault L, Pérot G, Chibon F, Bonnin S,
Lagarde P, Terrier P, Coindre JM and Aurias A: New insights in
sarcoma oncogenesis: A comprehensive analysis of a large series of
160 soft tissue sarcomas with complex genomics. J Pathol.
223:64–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schaefer IM, Cote GM and Hornick JL:
Contemporary sarcoma diagnosis, genetics, and genomics. J Clin
Oncol. 36:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Krystel-Whittemore M, Taylor MS, Rivera M,
Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Deshpande V,
Chebib I, Nielsen GP, et al: Novel and established EWSR1 gene
fusions and associations identified by next generation sequencing
and fluorescence in-situ hybridization. Hum Pathol. 93:65–73. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang X, Li Q, Xu B, Hu S, Wang Q, Li Y,
Zong Y, Zhang S and Li C: Mutation landscape and tumor mutation
burden analysis of Chinese patients with pulmonary sarcomatoid
carcinomas. Int J Clin Oncol. 24:1061–1068. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng B, Qu Y, Wang J, Shi Y and Yan W:
Pathogenic and targetable genetic alterations in resected recurrent
undifferentiated pleomorphic sarcomas identified by targeted
next-generation sequencing. Cancer Genomics Proteomics. 16:221–228.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nagy A, Bhaduri A, Shahmarvand N,
Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S and Ohgami RS:
Next-generation sequencing of idiopathic multicentric and
unicentric Castleman disease and follicular dendritic cell
sarcomas. Blood Adv. 2:481–491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nakashima R, Fujita M, Enomoto T, Haba T,
Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, et al:
Alteration of p16 and p15 genes in human uterine tumours. Br J
Cancer. 80:458–467. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Toguchida J, Yamaguchi T, Ritchie B,
Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki
MS, Little JB, et al: Mutation spectrum of the p53 gene in bone and
soft tissue sarcomas. Cancer Res. 52:6194–6199. 1992.PubMed/NCBI
|
|
43
|
Quinlan DC, Davidson AG, Summers CL,
Warden HE and Doshi HM: Accumulation of p53 protein correlates with
a poor prognosis in human lung cancer. Cancer Res. 52:4828–4831.
1992.PubMed/NCBI
|
|
44
|
Li JP, Zhang XM, Zhang Z, Zheng LH, Jindal
S and Liu YJ: Association of p53 expression with poor prognosis in
patients with triple-negative breast invasive ductal carcinoma.
Medicine (Baltimore). 98:e154492019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cho SY, Park C, Na D, Han JY, Lee J, Park
OK, Zhang C, Sung CO, Moon HE, Kim Y, et al: High prevalence of
TP53 mutations is associated with poor survival and an EMT
signature in gliosarcoma patients. Exp Mol Med. 49:e3172017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tsuchiya T, Sekine K, Hinohara S, Namiki
T, Nobori T and Kaneko Y: Analysis of the p16INK4, p14ARF, p15,
TP53, and MDM2 genes and their prognostic implications in
osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 120:91–98.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang HY, Illei PB, Zhao Z, Mazumdar M,
Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P and Ladanyi M:
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion:
A highly lethal subset associated with poor chemoresponse. J Clin
Oncol. 23:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oshiro Y, Chaturvedi V, Hayden D, Nazeer
T, Johnson M, Johnston DA, Ordóñez NG, Ayala AG and Czerniak B:
Altered p53 is associated with aggressive behavior of
chondrosarcoma: A long term follow-up study. Cancer. 83:2324–2334.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Antonescu CR, Tschernyavsky SJ, Decuseara
R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum
JR and Ladanyi M: Prognostic impact of P53 status, TLS-CHOP fusion
transcript structure, and histological grade in myxoid liposarcoma:
A molecular and clinicopathologic study of 82 cases. Clin Cancer
Res. 7:3977–3987. 2001.PubMed/NCBI
|
|
50
|
Italiano A, Di Mauro I, Rapp J, Pierron G,
Auger N, Alberti L, Chibon F, Escande F, Voegeli AC, Ghnassia JP,
et al: Clinical effect of molecular methods in sarcoma diagnosis
(GENSARC): A prospective, multicentre, observational study. Lancet
Oncol. 17:532–538. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Llombart B, Monteagudo C, Sanmartin O,
López-Guerrero JA, Serra-Guillén C, Poveda A, Jorda E,
Fernandez-Serra A, Pellín A, Guillén C and Llombart-Bosch A:
Dermatofibrosarcoma protuberans: A clinicopathological,
immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study
of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad
Dermatol. 65:564–575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kammerer-Jacquet SF, Thierry S, Cabillic
F, Lannes M, Burtin F, Henno S, Dugay F, Bouzillé G, Rioux-Leclercq
N, Belaud-Rotureau MA and Stock N: Differential diagnosis of
atypical lipomatous tumor/well-differentiated liposarcoma and
dedifferentiated liposarcoma: Utility of p16 in combination with
MDM2 and CDK4 immunohistochemistry. Hum Pathol. 59:34–40. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kim SK and Park YK: Ewing sarcoma: A
chronicle of molecular pathogenesis. Hum Pathol. 55:91–100. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
El Beaino M, Araujo DM, Lazar AJ and Lin
PP: Synovial sarcoma: Advances in diagnosis and treatment
identification of new biologic targets to improve multimodal
therapy. Ann Surg Oncol. 24:2145–2154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pierron G, Tirode F, Lucchesi C, Reynaud
S, Ballet S, Cohen-Gogo S, Perrin V, Coindre JM and Delattre O: A
new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat
Genet. 44:461–466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yoshida A, Goto K, Kodaira M, Kobayashi E,
Kawamoto H, Mori T, Yoshimoto S, Endo O, Kodama N, Kushima R, et
al: CIC-rearranged Sarcomas: A study of 20 cases and comparisons
with Ewing sarcomas. Am J Surg Pathol. 40:313–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Michal M, Berry RS, Rubin BP, Kilpatrick
SE, Agaimy A, Kazakov DV, Steiner P, Ptakova N, Martinek P,
Hadravsky L, et al: EWSR1-SMAD3-rearranged Fibroblastic Tumor: An
Emerging Entity in an Increasingly More Complex Group of
Fibroblastic/Myofibroblastic Neoplasms. Am J Surg Pathol.
42:1325–1333. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chiang S, Cotzia P, Hyman DM, Drilon A,
Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, et
al: NTRK fusions define a novel uterine sarcoma subtype with
features of fibrosarcoma. Am J Surg Pathol. 42:791–798. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fletcher JA and Rubin BP: KIT mutations in
GIST. Curr Opin Genet Dev. 17:3–7. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ren W and Gu G: Prognostic implications of
RB1 tumour suppressor gene alterations in the clinical outcome of
human osteosarcoma: A meta-analysis. Eur J Cancer Care (Engl).
262017.doi: 10.1111/ecc.12401.
|
|
61
|
Müller L, Hainberger D, Stolz V, Hamminger
P, Hassan H, Preglej T, Boucheron N, Sakaguchi S, Wiegers GJ,
Villunger A, et al: The corepressor NCOR1 regulates the survival of
single-positive thymocytes. Sci Rep. 7:159282017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Noblejas-Lopez MDM, Morcillo-Garcia S,
Nieto-Jimenez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM,
Pandiella A and Ocaña A: Evaluation of transcriptionally regulated
genes identifies NCOR1 in hormone receptor negative breast tumors
and lung adenocarcinomas as a potential tumor suppressor gene. PLoS
One. 13:e02077762018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang W, Song XW, Bu XM, Zhang N and Zhao
CH: PDCD2 and NCoR1 as putative tumor suppressors in gastric
gastrointestinal stromal tumors. Cell Oncol (Dordr). 39:129–137.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kanojia D, Nagata Y, Garg M, Lee DH, Sato
A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, et al:
Genomic landscape of liposarcoma. Oncotarget. 6:42429–42444. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Binh MB, Sastre-Garau X, Guillou L, de
Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I and Coindre JM:
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing
well-differentiated and dedifferentiated liposarcoma subtypes: A
comparative analysis of 559 soft tissue neoplasms with genetic
data. Am J Surg Pathol. 29:1340–1347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang Z, Chen H, Chen M, He X, Wang Y and
Zhang H: Application of COL1A1-PDGFB fusion gene detection by
fluorescence in situ hybridization in biopsy tissue of
dermatofibrosarcoma protuberans. J Dermatol. 44:798–802. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bianchi G, Sambri A, Pedrini E, Pazzaglia
L, Sangiorgi L, Ruengwanichayakun P, Donati D, Benassi MS and Righi
A: Histological and molecular features of solitary fibrous tumor of
the extremities: Clinical correlation. Virchows Arch. 476:445–454.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ogura K, Hosoda F, Arai Y, Nakamura H,
Hama N, Totoki Y, Yoshida A, Nagai M, Kato M, Arakawa E, et al:
Integrated genetic and epigenetic analysis of myxofibrosarcoma. Nat
Commun. 9:27652018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rogozhin DV, Bulycheva IV, Konovalov DM,
Talalaev AG, Roshchin VY, Ektova AP, Bogoroditsky YS, Strykov VA,
Kazakova AN, Olshanskaya YV, et al: Classical osteosarcoma in
children and adolescent. Arkh Patol. 77:68–74. 2015.(In Russian).
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mans DR, Budhu Lall AE, Macnack VL, van
Tholl JA, Zandveld EB and Vrede MA: Incidence, and gender, age and
ethnic distribution of sarcomas in the republic of Suriname from
1980 to 2008. West Indian Med J. 63:121–127. 2014.PubMed/NCBI
|
|
71
|
Knepper TC, Montesion M, Russell JS, Sokol
ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z,
Khushalani NI, et al: The genomic landscape of Merkel cell
carcinoma and clinicogenomic biomarkers of response to immune
checkpoint inhibitor therapy. Clin Cancer Res. 25:5961–5971. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cote GM, He J and Choy E: Next-generation
sequencing for patients with sarcoma: A single center experience.
Oncologist. 23:234–242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen X, Bahrami A, Pappo A, Easton J,
Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al:
Recurrent somatic structural variations contribute to tumorigenesis
in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Trabucco SE, Ali SM, Sokol E, Schrock AB,
Albacker LA, Chung J, Xavier MF, Disel U, Miller VA, Ross JS, et
al: Frequency of genomic biomarkers of response to immunotherapy in
sarcoma. J Clin Oncol. 36:11579. 2018. View Article : Google Scholar
|
|
76
|
Lange AM and Lo HW: Inhibiting TRK
proteins in clinical cancer therapy. Cancers (Basel). 10:1052018.
View Article : Google Scholar
|
|
77
|
Wong V, Pavlick D, Brennan T, Yelensky R,
Crawford J, Ross JS, Miller VA, Malicki D, Stephens PJ, Ali SM and
Ahn H: Evaluation of a congenital infantile fibrosarcoma by
comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion
responsive to Crizotinib. J Natl Cancer Inst. 108:djv3072016.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nagasubramanian R, Wei J, Gordon P,
Rastatter JC, Cox MC and Pappo A: Infantile fibrosarcoma with
NTRK3-ETV6 fusion successfully treated with the tropomyosin-related
kinase inhibitor LOXO-101. Pediatric Blood Cancer. 63:1468–1470.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bender J, Anderson B, Bloom DA, Rabah R,
McDougall R, Vats P and Mody R: Refractory and metastatic infantile
fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable
response to crizotinib. Cold Spring Harb Mol Case Stud.
5:a0033762019. View Article : Google Scholar : PubMed/NCBI
|
